Dna repair drugs market

DNA Repair Drugs Market, by Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), and Others), by Application (Ovarian cancer, Fallopian Tube cancer, Peritoneal cancer, Breast cancer and Gastric cancer) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Request Free Sample

Aug 2019
CMI2617
206 Pages
Excel & Pdf
Pharmaceutical

Summary

DNA Repair Drugs Market – Breakthrough for Cancer Patients

DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage results in genetic disorders, however the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs such as PARP inhibitors and other DNA repair drugs help to treat diseases with genetic aberrations.

The global DNA repair drugs market size was valued at US$ 461.3 Mn in 2017, and is expected to exhibit a CAGR of 32.4% over the forecast period (2018–2026).

Figure 1. Global DNA Repair Drugs Market Value (US$ Mn), by Region, 2018

Source: Coherent Market Insights Analysis (2019)

Increasing incidence of cancer, rising government initiatives to promote awareness for cancer treatment, and expansion strategies by manufacturers to increase and expand their product portfolio in the international markets are factors propelling growth of the global DNA repair drugs market

Increasing incidence of cancer is expected to drive the global DNA repair drugs market growth over the forecast period. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for the second highest number of cancer cases (2,088,849 new cases) across the globe in 2018. According to GLOBOCAN, 43.6% new cases of breast cancer were registered in Asia Pacific in 2018.

Moreover, increasing drug approval by key players in order to address demand for efficient therapeutics, is expected to propel growth of the market over the forecast period. In October 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for Talazoparib (Talzenna) for treating patients with HER2 (negative locally advanced or metastatic breast cancer).

However, Delays in regulatory approvals lead to delay in marketing of the product, which can adversely affect the revenue generation of the manufacturer. Similarly, delay in post approval of the drug product for other therapeutic indication results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products.

Figure 2. Global DNA Repair Drugs Market Share (%), by Drug Type, (2018-2026)

Source: Coherent Market Insights Analysis (2019)

Rising prevalence of cancer, as well as increasing collaborations and acquisitions by key players is expected to boost the market growth

North America is expected to dominate the global DNA repair drugs market over the forecast period owing to increasing incidence of cancer. According to the American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed in the U.S. Moreover, increasing demand for cancer treatments is expected to drive growth of the DNA repair drugs market in the region.

Market players are engaged in research and development activities in order to meet the rising demand DNA repair drugs. In May 2019, Clovis Oncology, Inc., collaborated with Bristol-Myers Squibb Company and Foundation Medicine Inc. to initiate phase II study for evaluating rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometroid ovarian cancer.

Key Players

Major players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

Table of Content

Table of Contents

Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

Market Purview

Report Description

Market Definition and Scope

Executive Summary

Market Snippet, By Drug Type
Market Snippet, By Application
Market Snippet, By Distribution Channel
Market Snippet, By Region

Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities

Global DNA Repair Drugs Market, By Drug Type, 2018 – 2026, (US$ Mn)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends

Niraparib (Zejula)

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Olaparib (Lynparza)

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Rucaparib (Rubraca)

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Talazoparib (Talzenna)

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Global DNA Repair Drugs Market, By Application, 2018 – 2026, (US$ Mn)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends

Ovarian Cancer

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Breast Cancer

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Global DNA Repair Drugs Market , By Distribution Channel, 2018 – 2026, (US$ Mn)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends

Hospital Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Retail Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Online Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)

Global DNA Repair Drugs Market , By Region, 2018 – 2026, (US$ Mn)

Introduction

Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026

North America

Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)

U.S.
Canada

Latin America

Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)

Brazil
Mexico
Argentina
Rest of Latin America

Europe

Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)

GCC
Israel
Rest of Middle East

Africa

Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)

South Africa
Central Africa
North Africa

Competitive Landscape

Company Profiles

AstraZeneca Plc.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Johnson & Johnson

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

GlaxoSmithKline plc.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Pfizer, Inc.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Clovis Oncology Inc.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

AbbVie Inc.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Bristol Myers Squibb

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Merck KGaA

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Genentech, Inc.

Company Overview
Product Type Portfolio
Key Highlights
Market Strategies

Artios Pharma

Company Overview
Product Type Portfolio
Key Highlights
Market Strategies

Repare Therapeutics Inc.

Company Overview
Product Type Portfolio
Key Highlights
Market Strategies

Sierra Oncology, Inc.

Company Overview
Product Type Portfolio
Key Highlights
Market Strategies

Karyopharm Therapeutics Inc.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Ono Pharmaceutical Co., Ltd.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Jiangsu Hengrui Medicine Co., Ltd.

Company Overview
Product Type Portfolio
Financial Overview
Key Highlights
Market Strategies

Section

References
Research Methodology
About us and Sales Contact

*Browse 31 market data tables and 24 figures on "DNA Repair Drugs Market - Global forecast to 2026”.

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What are the growth estimates for DNA repair drugs market till 2026?

The global DNA repair drugs market is estimated to surpass US$ 8,378.1 Million by 2026.

Which are the prominent DNA repair drugs market players across the globe?

Major players operating in the global DNA repair drugs market include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

What are the key factors hampering growth of the DNA repair drugs market?

Delays in regulatory approvals lead to delay in marketing of the product and this is one of the major factors that is expected to hamper growth of the market over the forecast period.

What are the key factors driving growth of the DNA repair drugs market?

Increasing incidence of canceris one of the major factors that is expected to propel growth of the market over the forecast period.

What is the compound annual growth rate (CAGR) of the DNA repair drugs market for next 8 years?

The global DNA repair drugs market is estimated to exhibit a CAGR of 32.4% over the forecast period.

Which region is dominating the DNA repair drugs market growth?

Among regions, North Americais expected to hold dominant position in the DNA repair drugs market over the forecast period.